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Abstract Lisofylline (LSF), is the R-(-) enantiomer of
the metabolite M1 of pentoxifylline, and is currently under
development for the treatment of type 1 diabetes. The aim
of the study was to develop a physiologically based phar-
macokinetic (PBPK) model of LSF in mice and to perform
simulations in order to predict LSF concentrations in hu-
man serum and tissues following intravenous and oral ad-
ministration. The concentrations of LSF in serum, brain,
liver, kidneys, lungs, muscle, and gut were determined at
different time points over 60 min by a chiral HPLC method
with UV detection following a single intravenous dose of
LSF to male CD-1 mice. A PBPK model was developed to
describe serum pharmacokinetics and tissue distribution of
LSF using ADAPT II software. All pharmacokinetic pro-
files were fitted simultaneously to obtain model parameters.
The developed model characterized well LSF disposition in
mice. The estimated intrinsic hepatic clearance was
5.427 ml/min and hepatic clearance calculated using the
well-stirred model was 1.22 ml/min. The renal clearance of
LSF was equal to zero. On scaling the model to humans, a
good agreement was found between the predicted by the
model and presented in literature serum LSF concentra-
tion–time profiles following an intravenous dose of 3 mg/
kg. The predicted LSF concentrations in human tissues
following oral administration were considerably lower
despite the twofold higher dose used and may not be suf-
ficient to exert a pharmacological effect. In conclusion, the
mouse is a good model to study LSF pharmacokinetics
following intravenous administration. The developed
PBPK model may be useful to design future preclinical and
clinical studies of this compound.
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1 Introduction
Lisofylline (LSF), (-)-R-1-(5-hydroxyhexyl)-3,7-dimethy-
lxanthine (Fig. 1), is an enantiomer of the metabolite M1 of
pentoxifylline. It is currently under development for the
treatment of type 1 diabetes (Yang et al. 2005; National
Institutes of Health 2009). LSF reduces the impairment of
insulin secretion induced by IL-1b in cultured rat islet cells
(Bleich et al. 1996), suppresses IFN-c production, the onset
of diabetes, and macrophage infiltration into islets from
NOD mice (Yang et al. 2002), as well as it improves in-
sulin response and lowers glucose levels in streptozotocin-
treated rats after the oral glucose tolerance test (Striffler
and Nadler 2004). It has been shown that LSF prevents b
cell dysfunction in NOD mice by inhibition of STAT4
phosphorylation which interrupts IL-12 signaling (Yang
et al. 2003). Moreover, this compound ameliorates ex-
perimental allergic encephalomyelitis in mice (Bright et al.
1998). As a STAT 4 inhibitor it may be also potentially
useful in other autoimmune disorders (Liang et al. 2014).
LSF has been shown to inhibit lysophosphatidic acid
acyltransferase with an IC50 of 0.6 lM in lipopolysaccha-
ride (LPS) stimulated P388 cell line (Rice et al. 1994a). It
is well known that phosphatidic acid (PA) is a crucial
mediator involved in pro-inflammatory cytokine release,
acting via Akt–mTOR–p70 S6K pathway. LSF also im-
proves survival in mice injected with a lethal dose of LPS
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(Rice et al. 1994a) and ameliorates sepsis-induced lung
injury in minipigs (Hasegawa et al. 1997). Moreover, in
rats given IL-1 intratracheally LSF pretreatment reduced
lung leak but did not decrease neutrophil accumulation in
lungs (Hybertson et al. 1997). However, clinical trials of
LSF for the treatment of acute lung injury or acute respi-
ratory distress syndrome showed no evidence of improved
survival rate of patients with serious infections, or organ
failure-free days, and decreased free fatty acids in serum
(ARDS Clinical Trials Network et al. 2002). LSF is also
known to suppress release of TNF-a in vivo in mice (Rice
et al. 1994a; Wyska 2009, 2010a) and ex vivo in human
blood stimulated with endotoxin derived from Salmonella
or Escherichia coli (Rice et al. 1994b). In addition, it ab-
rogates the synthesis of TNF-a or IL-1b and stimulates the
production of IL-10 in human leukocytes in vitro (van
Furth et al. 1997). Mice treated with LSF after hemorrhage
exhibited reduced lung edema, intraalveolar hemorrhage,
pulmonary interstitial neutrophils and BAL leukocytes
compared to untreated mice (Abraham et al. 1995). In
patients receiving the allogenic bone marrow transplanta-
tion the treatment with 3 mg/kg LSF resulted in an im-
proved 100-day survival compared to placebo or 2 mg/kg
LSF treated patients (List et al. 2000). Treatment with LSF
improves hematological recovery after 5-fluorouracil
treatment possibly by inhibition of TGF-b and abrogates
the release of hematopoietic inhibitors induced by che-
motherapy in mice (Clarke et al. 1996; Vries and Singer
2000). However, in humans LSF treatment failed to alter
the toxicities of high-dose IL-2 in renal cancer or malignant
melanoma patients (Margolin et al. 1997).
In order to exert its pharmacologic activity the drug
should attain therapeutic concentrations at the site of ac-
tion. One of the reasons for the lack of efficacy in clinical
trials may be inappropriate concentration of the drug in the
target tissues. Physiologically based pharmacokinetic
(PBPK) modeling in animals allows for the prediction of
drug concentration both in human plasma and tissues.
Classical pharmacokinetic models consist of a small
number of compartments (1–3 in most cases) that have a
limited physiological meaning. They are useful to estimate
pharmacokinetic parameters but have many limitations.
PBPK models include a larger number of compartments
corresponding to anatomical spaces and intercompartmen-
tal blood flow as well as incorporate the biochemical and
physiochemical parameters of the drug under investigation.
They are very useful not only to describe pharmacokinetics
of a drug, but also to extrapolate a dose between species or
populations or routes of administration (Jones et al. 2006).
Pharmacokinetic properties of LSF following intravenous
and oral administration were previously studied in mice
(Wyska et al. 2006, 2007, Wyska 2010b). Limited infor-
mation exists on the pharmacokinetics of LSF in human
subjects. Only in one human study the pharmacokinetics of
this compound in plasma was assessed after a short intra-
venous infusion and oral administration using noncom-
partmental analysis (Bursten et al. 1998).
The aim of this study was to develop a PBPK model
using plasma and tissue concentration–time data obtained
following intravenous administration of LSF to mice.
Moreover, based on this model and human organ weights,
blood flows and biochemical data, simulations were per-
formed to predict LSF concentrations in human serum and
tissues following intravenous and oral administration of
this compound.
2 Materials and methods
2.1 Chemicals
Lisofylline was obtained in the Department of Technology
and Biotechnology of Drugs, Jagiellonian University Col-
legium Medicum. Temazepam was a gift from Polfa
(Poland). All other chemicals were of HPLC or analytical
reagent grade and were purchased from Merck (Darmstadt,
Germany).
2.2 Pharmacokinetic study
Male Crl:CD-1 (8–10 weeks old) mice weighing
30.25 ± 2.11 g, bred in-house from progenitors obtained
from Charles River Laboratories (Sulzfed, Germany) were
used in this study. Animals were fasted overnight prior to
drug administration but had free access to water. All ani-
mal procedures were approved by the Local Ethical
Committee on Animal Testing at the Jagiellonian Univer-
sity in Cracow. LSF (50 mg/kg) was given into the tail
vein, and animals (3–4 per time point) were exsanguinated
at different time points after compound administration up
to 60 min. Tissues, such as brain, muscle, kidneys, liver,
gut, and lungs were harvested. Blood was allowed to clot at
room temperature for 15–20 min and then centrifuged for
20 min (1,5009g). All samples were stored at -80 C
until assayed.Fig. 1 Chemical structure of LSF
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2.3 Analytical method
LSF serum concentrations were determined by a previously
described chiral HPLC method (Wyska et al. 2006).
Briefly, each tissue was homogenized in 0.1 M phosphate
buffered saline (1:4 w/v). Serum (0.2 ml) or tissue ho-
mogenates (1 ml) were mixed with temazepam (internal
standard). Then the samples were acidified with 40 ll 1 M
HCl and extracted with 5 ml of dichloromethane. After
centrifugation (1,0009g, 15 min), the organic layer was
transferred to a new tube, then evaporated to dryness at
37 C under a gentle stream of nitrogen. The residue was
dissolved in 100 ll of mobile phase, and 50 ll of this so-
lution was injected into the HPLC system. The HPLC
system (Thermo Separation Products, San Jose, CA, USA)
consisted of a P100 isocratic pump, a Rheodyne 7,125
injector (Rheodyne, Cotati, CA, USA) with a 50-ll sample
loop, an UV100 variable-wavelength UV/VIS detector,
operating at 275 nm, and an SP4400 (ChromJet) integrator.
All analyses were performed at ambient temperature on a
250 mm 9 4.6 mm Chiralpak AD column (Daicel Corp.,
Japan) with 10 lm particles, protected with a
20 mm 9 4.6 mm LC-Si guard-column (Supelco Inc.,
Bellefonte, PA, USA). The mobile phase consisting of
hexane-2-propanol-diethylamine (78:22:0.01 v/v/v) was
pumped at a flow rate of 1 ml/min. The method was linear
from 0.05 to 60 lg/ml. The intra-day and inter-day preci-
sions were less than 10 % and the recovery ranged from 72
to 95 % depending on the type of tissue.
2.4 Physiologically based pharmacokinetic model
The PBPK model used to describe pharmacokinetics of
LSF included separate compartments for each studied tis-
sue as well as the arterial and venous plasma compartments
(Fig. 2). It was assumed that the compartments were well
mixed and the drug concentration in venous plasma leaving
a tissue was in equilibrium with that in the tissue. All non-
sampled tissues were pooled together into a remainder
compartment.
Changes of drug concentrations over time in individual
compartments were described by the following mass-bal-
ance differential equations:
Brain (Br)
VBr  dCBr
dt
¼ QBr  ðCA 
CBr
PBr
Þ ð1Þ
Muscle (Mu)
VMu  dCMu
dt
¼ QMu  ðCA 
CMu
PMu
Þ ð2Þ
Kidneys (Ki)
VKi  dCKi
dt
¼ QKi  ðCA 
CKi
PKi
Þ  CLR  CA ð3Þ
Liver (Li)
VLi  dCLi
dt
¼ CA  ðQLi  QGuÞ þ QGu  ð
CGu
PGu
Þ  QLi
 ðCLi
PLi
Þ  Vmax
fuT  CLi þ KM  PLi
 fuT  CLi
ð4Þ
Gut (Gu)
VGu  dCGu
dt
¼ QGu  ðCA 
CGu
PGu
Þ ð5Þ
Lungs (Lu)
VLu  dCLu
dt
¼ QLu  ðCV 
CLu
PLu
Þ ð6Þ
Fig. 2 Physiologically based
model for the pharmacokinetics
of LSF in mice
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Remainder (Re)
VRe  dCRe
dt
¼ QRe  ðCA  CReÞ ð7Þ
Arterial blood (A)
VA  dCA
dt
¼ QLu  ð
CLu
PLu
 CAÞ ð8Þ
Venous blood (V)
VV  dCV
dt
¼ ½QBr  ð
CBr
PBr
Þ þ QMu  ð
CMu
PMu
Þ þ QKi  ð
CKi
PKi
Þ
þ QLi  ð
CLi
PLi
Þ þ QRe  CRe þ InðtÞ  QLu
 CV;
ð9Þ
where V is tissue weight or volume, Q is blood flow, P
represents the tissue-to-serum partition coefficient, CLR is
the renal clearance, Vmax represents the maximum rate of
metabolism, KM is the LSF concentration at which
metabolism is occurring at 50 % of the maximum rate,
In(t) is the drug input rate, and fuT is the fraction unbound
in the liver. It was assumed that the compound was
distributed homogenously throughout liver water and that
the unbound concentrations in liver water and serum were
identical. The fraction unbound in murine serum was
assumed to be 0.76 (authors’ own unpublished data
obtained ex vivo using ultrafiltration). The model
parameters, such as blood flows and tissue weights or
volumes that were not estimated, were obtained from the
literature. The tissue-to-serum partition coefficients were
calculated using the area method proposed by Gallo et al.
(1987) (Table 1). The areas under the serum and tissue
concentration–time curves (AUCs) were estimated by the
linear trapezoidal rule with Phoenix WinNonlin v. 6.3
(Certara USA, Inc., St Louis, MO). The PBPK model
(Fig. 2) was fitted simultaneously to 7 mean concentration
versus time profiles following intravenous LSF
administration to mice. The initial conditions for Eqs. 1–
8 were set to zero. The maximum likelihood method in the
ADAPT II software (D’Argenio and Schumitzky 1997)
was used to estimate unknown model parameters. The
model of variance was as follows:
var Cð Þ ¼ ðr1 þ r2  YÞ2 ð10Þ
where Y is the model-predicted LSF concentration, and r1
and r2 are the variance model parameters. The goodness-
of-fit was assessed using standard criteria (Gabrielsson and
Weiner 1997).
Based on the developed PBPK model and human tissue
weights or volumes and blood flows, LSF concentration–
time profiles were simulated in serum and tissues in human
subjects following intravenous or oral administration.
Model parameters used for these predictions are listed in
Table 2. It was assumed that P values did not differ be-
tween species. Because in humans LSF is metabolized via
more than one pathway, the intrinsic clearances of these
pathways were summed up. The values of Vmax and KM
obtained using human liver microsomes were taken from
literature (Lee and Slattery 1997; Shin and Slattery 1998).
In vivo whole liver intrinsic clearance (CLint) was calcu-
lated according to the following equation (Edwards et al.
2011):
CLintinvivo ¼
XVmaxðiÞ
KMðiÞ
 45 mg of microsomal protein
g of liver weight
 liver weight
ð11Þ
where Vmax(i) is maximum metabolic rate for enzyme i and
KM is Michaelis–Menten constant for enzyme i.Table 1 Fixed parameters for the PBPK model of LSF in mice
(Brown et al. 1997; Davies and Morris 1993)
Tissue Blood flow
(ml/min)a
Weight
or volume
(g or ml)b
Tissue-to-serum
partition
coefficient (P)
Brain 0.47 0.50 0.345
Muscle 0.91 11.40 0.640
Kidneys 1.27 0.50 0.777
Liver 2.25 1.65 0.859
Gut 1.50 1.50 0.892
Lungs 13.98 0.22 0.758
Remainder 7.58 13.05 –
Arterial blood – 0.24 –
Venous blood – 0.94 –
a Blood flow to remainder was calculated as the difference between
the blood flow to lungs and the sum of blood flows to the other tissues
b Weight of remainder was calculated as the difference between total
body weight (30 g) and the sum of the other tissue weights
Table 2 Parameters for the PBPK model of LSF used for simulations
of pharmacokinetics and tissue distribution of this compound in a
70-kg human subject (Brown et al. 1997; Davies and Morris 1993)
Tissue Blood flow (ml/min) Weight or volume (g or ml)
Brain 700 1,400
Muscle 750 35,000
Kidneys 1,240 310
Liver 1,450 1,800
Gut 1,100 1,650
Lungs 5,600 1,000
Remainder 360 24,290
Arterial blood – 1,000
Venous blood – 3,550
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As LSF has a linear pharmacokinetics in humans (Bur-
sten et al. 1998), for simulations a single parameter, CLint
in vivo was used in Eq. 4 to describe the rate of LSF hepatic
metabolism.
The in vivo hepatic plasma clearance (CLH) was sub-
sequently calculated using the modified well-stirred model
(Wilkinson and Shand 1975):
CLH ¼
QH  fu  CLint
QH þ fu  CLint=ðCB=CpÞ
; ð12Þ
where fu is the fraction unbound in plasma. For LSF the
value of fu in human plasma is 0.54, whereas blood to
plasma LSF concentration ratio (CB/Cp) is 0.77 (Nicklas-
son et al. 2002).
For simulations of the time courses of LSF concentra-
tions after oral administration to human subjects, the input
function, In(t) was described by the following equation:
InðtÞ ¼ F  Dose ka  ekat ð13Þ
where ka represents a first-order absorption rate constant,
F is the fraction of the dose absorbed following oral ad-
ministration, and t is time. The values of ka and F used for
simulations were obtained from a pharmacokinetic study in
mice and equaled 0.024 min-1 and 0.16, respectively
(Wyska et al. 2007).
The simulated concentration versus time profile ob-
tained in human serum after LSF administration at a dose
of 3 mg/kg as a short-term intravenous infusion over
10 min was compared with that available in literature
(Bursten et al. 1998). The data for comparison were ex-
tracted with Graph Digitizer software v. 2.0 (Brothersoft).
3 Results and discussion
PBPK models allow for the integration of physiological,
biochemical, and anatomical data from different sources to
estimate pharmacokinetic parameters and predict plasma
and tissue concentration–time profiles. The most important
advantages of developing PBPK models are the possibility
to investigate drug concentrations in animal organs that
could otherwise never be assessed in humans and the
possibility to extrapolate the model to higher species by
taking into account their organ volumes and blood flows,
and adjusting for the differences in metabolism, plasma
protein binding, and blood/plasma partition ratio between
species. In addition, PBPK modeling is a useful tool to gain
insights into the properties of a compound. The application
of these models in drug development has been limited for
many years mainly due to the mathematical complexity of
this approach and the labor-intensive input data required
for the model building process. Recent advances in the
prediction of intestinal absorption, hepatic metabolism, and
tissue distribution from in vitro data have resulted in more
frequent use of these models (Jones et al. 2006; Parrott
et al. 2005). Moreover, several PBPK simulation tools have
become commercially available (e.g., GastroPlus, Cloe PK,
or PK-Sim).
In the present study, this approach was used to evaluate
plasma pharmacokinetics and tissue distribution of a drug
candidate, LSF, in mice. The mean LSF concentration–
time profiles in serum and all sampled tissues following
intravenous administration of this compound are presented
in Fig. 3. LSF attained high concentrations in all tissues
comparable to those observed in serum with the exception
of brain, where concentrations measured were several
times lower. These observations are confirmed by the tis-
sue-to-serum partition coefficients (P) calculated based on
the areas under the concentration–time curves (AUCs)
listed in Table 1. The value of this coefficient was the
highest for the gut (0.892), followed by the liver tissue
(0.859), whereas the P value for the brain tissue was the
lowest (0.345). In mice this compound was eliminated
from the body very fast, and 60 min following dosing its
concentrations dropped below 1 lg/ml in most studied
tissues. All concentration versus time profiles were fitted
simultaneously using the PBPK model shown in Fig. 2.
The model-predicted profiles, shown in Fig. 3, demonstrate
good agreement with the experimental data. The values of
estimated model parameters are presented in Table 3. The
relatively low CV % values are also indicative of good
model fitting. The intrinsic clearance calculated based on
the estimated values of Vmax are KM was 5.427 ml/min.
Assuming that the blood to plasma ratio is constant across
species, the hepatic plasma clearance calculated according
to Eq. 12 is 1.22 ml/min. This value is close to in vivo total
clearance (1.44 ml/min) estimated based on the LSF serum
concentration–time profile obtained in the present study
using a one-compartment pharmacokinetic model in
Phoenix WinNonlin v. 6.3. PBPK modeling indicated
extremely low CLR of LSF in mice. Thus, the value of this
parameter was fixed to zero in the final model. This ob-
servation was confirmed by the results of the experiment
performed in our laboratory in order to assess a percent of
LSF excreted unchanged with urine. For this purpose, three
mice were given an intravenous dose of 50 mg/kg LSF and
they were placed in metabolic cages. All excreted urine
was collected after 2 and 4 h following LSF administration.
The volumes of urine samples were recorded and drug
concentrations in each sample were measured using the
chiral HPLC method described in the Sect. 2 after valida-
tion for murine urine. The calculated mean percentage of
LSF dose excreted unchanged with urine within 4 h was as
low as 0.71 ± 0.13 % (unpublished data).
The PBPK model and the final estimated parameters
(Table 3) were used to simulate the time course of LSF
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Fig. 3 Time course of observed (symbols) and PBPK model predicted (lines) LSF concentrations in serum and tissues
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concentrations in the arterial and remainder compartments
(Fig. 4). The simulated profile in the arterial compartment
indicates that LSF concentrations are similar in both arte-
rial and venous plasma; thus, rapid equilibrium between
both compartments occurred. LSF concentrations observed
in the remainder compartment increase more slowly to
relatively high peak values and decrease in parallel with
the terminal phase of LSF elimination in the other studied
tissues. This observation may have a clinical significance,
for example, in autoimmune disorders such as rheumatoid
arthritis, where drugs must reach their target sites in con-
centrations sufficient to exert their pharmacologic effects.
Figure 5 shows the LSF concentration–time profiles in
human serum and tissues after a 10 min intravenous infu-
sion and oral administration of a dose of 3 and 6 mg/kg,
respectively, simulated based on the PBPK model. The
blood flows and organ weights or volumes used for
simulations are presented in Table 2, whereas the in vivo
intrinsic clearance was determined from data obtained
using human livermicrosomes. It has been shown that LSF is
metabolized in human liver microsomes by the cytochrome
P450 to two principal metabolites, lisofylline 4,5-diol and
pentoxifylline. Lisofylline diol formation is biphasic, with
KM values of 0.0230 and 4.23 mM and the respective Vmax
values of 0.0565 and 0.429 nmol/min/mg of protein (Shin
and Slattery 1998). The low and high KM enzymes are
CYP3A4 and CYP2A6. Similarly, a biphasic model best
described the data for the formation of pentoxifylline from
LSF. KM values were 0.282 and 158 lM, and the respective
Vmax values equaled to 0.003 and 0.928 nmol/min/mg. The
low KM enzyme was not a cytochrome P450, whereas the
high-affinity enzyme was CYP1A2 (Lee and Slattery
1997). The in vivo whole liver intrinsic clearance of LSF
calculated based on these data and Eq. 11 was 1,545.24 ml/
min. As presented in Fig. 5, the predicted by the PBPK
model LSF concentration versus time profile in serum
following intravenous administration was very close to the
concentrations observed in human subjects receiving the
same dose of LSF by the same route of administration. The
plasma hepatic clearance calculated based on the in vivo
intrinsic clearance (Eq. 12) was 477.54 ml/min. This value
was considerably lower than the total clearance calculated
based on the data digitalized from the paper describing the
human study on LSF pharmacokinetics (1,282.88 ml/min)
(Bursten et al. 1998). Therefore, it can be assumed that
other pathways of LSF elimination than hepatic metabo-
lism exist in humans. An attempt was also made to
calculate the hepatic plasma clearance of LSF in
humans based on the hepatic clearance determined in
mice and blood flows according to the equation: human
clearance = animal clearance 9 (human liver blood flo-
w/animal liver blood flow) (Ward and Smith 2004). The
value of human clearance obtained using this method
cTable 3 Final PBPK model parameters of LSF
Parameter Estimate CV (%)
CLR (ml/min) 0 (fixed) –
Vmax (lg/min) 9.644 30.34
KM (lg/ml) 1.777 89.52
r1 0.311 15.50
r2 0.250 10.86
Fig. 4 Simulated LSF concentrations in the arterial (upper panel)
and remainder (lower panel) compartments in mice using the PBPK
model and estimated parameters
Fig. 5 PBPK-model simulated LSF concentration versus time pro-
files in human serum and tissues following a 10 min intravenous
infusion (solid line) and oral administration (dashed line) of an LSF
dose of 3 and 6 mg/kg, respectively. Symbols represent LSF
concentrations measured in plasma of human subjects receiving this
compound intravenously at a dose of 3 mg/kg (Bursten et al. 1998)
and dotted lines represent the pharmacokinetic profiles following oral
administration of a dose of 6 mg/kg predicted based on the human
oral absorption data (for more explanation see the text)
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(766.89 ml/min) was higher than that derived from in vitro
data, but still significantly lower than the total clearance of
LSF in humans.
The simulated profile obtained following oral dosing
was slightly different from the observed values. Following
an oral administration of a dose of 6 mg/kg LSF to human
subjects the maximum concentration (Cmax) was
226 ± 99.10 ng/ml and time to Cmax was 0.53 ± 0.26 h
(Bursten et al. 1998). The values of these parameters ob-
tained from the simulated concentration versus time curve
following the same oral dose of LSF (Fig. 5) were
572.12 ng/ml and 10.6 min, respectively. Despite an
overestimation of Cmax after oral administration, the model
describes the terminal slope satisfactorily. The discrepancy
between the pharmacokinetic parameters estimated from
observed and predicted data may be explained by the fact
that ka and F values used for simulations were estimated
based on the data obtained from mice (Wyska et al. 2007).
In humans the bioavailability of LSF was calculated to be
5.9 % (Bursten et al. 1998), whereas in mice this parameter
was 16 %. The dashed and dotted lines in Fig. 5 represent
simulations based on the values of ka and F obtained from
murine and human pharmacokinetic data, respectively. In
both cases, LSF concentrations in serum and tissues studied
were considerably lower in comparison to the profiles
obtained following intravenous administration of the
2-times lower dose, namely 3 mg/kg and may be insuffi-
cient to exert any pharmacological effect.
From Fig. 5 it seems that the mouse is a good model
to study LSF pharmacokinetics following intravenous
administration. It is not surprising as CYP3A plays an im-
portant role in LSF metabolism. In a comparison of several
species, the mouse was identified as the most similar to
humans with respect to catalytic activities of this isozyme
(Bogaards et al. 2000). However, in the case of oral dosing
the prediction was not perfect when incorporating phar-
macokinetic parameters obtained from mice into the model.
This may indicate different mechanisms involved in LSF
absorption from the gastrointestinal tract in both species.
4 Conclusions
In conclusion, pharmacokinetics of LSF following intra-
venous administration in mice have been presented and
assessed quantitatively using a PBPK model. The model
captured the experimental data very well. The predicted
LSF concentrations in human serum following intravenous
administration were very close to the observed concentra-
tions indicating that the mouse is a good model to study
pharmacokinetics of this compound. The developed PBPK
model may be useful in the design and analysis of future
preclinical and clinical studies of LSF.
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